Skip to main content

Cynthia Ann Moylan

Associate Professor of Medicine
Medicine, Gastroenterology
Duke Box 3256, 595 LaSalle GSRB 1, Durham, NC 27710
Duke South Clinic, 40 Medicine Circle, Room 0350, Durham, NC 27710

Overview


My research interests focus on the study of chronic liver disease and primary liver cancer, particularly from metabolic dysfunction associated steatotic liver disease (MASLD), formerly called nonalcoholic fatty liver disease (NAFLD).  As part of the MASLD Research Team at Duke, we are investigating the role of environmental contaminants, epigenetics, and genetics on the development of advanced fibrosis and liver cancer from MASLD and other chronic liver diseases.  We are also interested in understanding risks for progressive liver disease including developmental programming and in utero exposures and have been investigating these risks through studies of the Newborn Epigenetics Study (NEST).  The long term goal of our research is to develop non-invasive biomarkers to identify those patients at increased risk for cirrhosis and end stage liver disease in order to risk stratify patients as well as to develop better preventative and therapeutic strategies.

Current Appointments & Affiliations


Associate Professor of Medicine · 2022 - Present Medicine, Gastroenterology, Medicine
Associate Professor in Pathology · 2018 - Present Pathology, Clinical Science Departments
Member of the Duke Cancer Institute · 2014 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Osteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in MASH.

Journal Article Liver Int · April 2025 BACKGROUND AND AIMS: Osteopontin (OPN) promotes the ductular reaction and is a major driver of chronic liver disease (CLD) progression. Although CLD is characterised by the accumulation of inflammatory cells including macrophages around the peri-portal reg ... Full text Link to item Cite

The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints.

Journal Article Am J Gastroenterol · March 1, 2025 INTRODUCTION: One of the primary goals of the Liver Cirrhosis Network (LCN) is to develop a cohort study to better understand and predict the risk of hepatic decompensation and other clinical and patient-reported outcomes among patients with Child A cirrho ... Full text Link to item Cite

Current and emerging strategies for the prevention of hepatocellular carcinoma.

Journal Article Nat Rev Gastroenterol Hepatol · March 2025 Liver cancer is the third leading cause of cancer-related deaths globally, with incident cases expected to rise from 905,700 in 2020 to 1.4 million by 2040. Hepatocellular carcinoma (HCC) accounts for about 80% of all primary liver cancers. Viral hepatitis ... Full text Link to item Cite
View All Publications

Recent Grants


Genomic Imprinting in the Development of NAFLD

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2028

Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis

ResearchCo-Principal Investigator · Awarded by University of Texas - Southwestern · 2023 - 2027

The Southeastern Liver Health Cohort Study

ResearchPrincipal Investigator · Awarded by North Carolina State University · 2023 - 2027

View All Grants

Education, Training & Certifications


University of Miami · 2002 M.D.